Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Chimerix, Inc.
Chimerix, Inc. News
Apr 21, 2025 - prnewswire.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Mar 31, 2025 - seekingalpha.com
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Mar 21, 2025 - globenewswire.com
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
Mar 10, 2025 - businesswire.com
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Chimerix, Inc. Quantitative Score
About Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Chimerix, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Chimerix, Inc. Financials
Table Compare
Compare CMRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | CMRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CMRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CMRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CMRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Chimerix, Inc. Income
Chimerix, Inc. Balance Sheet
Chimerix, Inc. Cash Flow
Chimerix, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Chimerix, Inc. Executives
| Name | Role |
|---|---|
| Mr. Michael T. Andriole M.B.A. | Chief Executive Officer, President & Director |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior Vice President, General Counsel & Corporate Secretary |
| Dr. Joshua E. Allen Ph.D. | Chief Scientific Officer |
| Ms. Michelle LaSpaluto | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Michael T. Andriole M.B.A. | Chief Executive Officer, President & Director | Male | 1973 | 1.05M |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer | 1965 | 781.25K | |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior Vice President, General Counsel & Corporate Secretary | 1970 | 692.74K | |
| Dr. Joshua E. Allen Ph.D. | Chief Scientific Officer | -- | ||
| Ms. Michelle LaSpaluto | Chief Financial Officer | Female | 1975 | -- |
Chimerix, Inc. Insider Trades
| Date | 21 Apr |
| Name | Vakiener Victoria |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 60000 |
| Date | 21 Apr |
| Name | Vakiener Victoria |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 35000 |
| Date | 21 Apr |
| Name | Vakiener Victoria |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 50000 |
| Date | 21 Apr |
| Name | Vakiener Victoria |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 60000 |
| Date | 21 Apr |
| Name | Vakiener Victoria |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 60000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 Apr | Vakiener Victoria | Director | Disposed | D-Return | 60000 |
| 21 Apr | Vakiener Victoria | Director | Disposed | D-Return | 35000 |
| 21 Apr | Vakiener Victoria | Director | Disposed | D-Return | 50000 |
| 21 Apr | Vakiener Victoria | Director | Disposed | D-Return | 60000 |
| 21 Apr | Vakiener Victoria | Director | Disposed | D-Return | 60000 |